SPRB

Over the past six months, Spruce Biosciences' stock price has experienced significant volatility. The share price saw a substantial increase of 499.69% between September 15, 2025, and May 5, 2026, and has gained 934.7% over the past 12 months. In April 2026, the company announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $60 million, which led to a stock price decrease of 26.05%. In March 2026, the company reported its full-year 2025 financial results and provided corporate updates, including completing positive Type B FDA meetings for TA-ERT and securing a loan facility. In May 2026, Spruce Biosciences appointed a Vice President of Market Access and a Vice President of Commercial Operations. In October 2025, TA-ERT received FDA Breakthrough Therapy Designation. In March 2026, Spruce Biosciences terminated its collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for tildacerfont in Japan.